Drug Development Pipeline
This program aims to deliver a functional CFTR gene directly into the lung cells of people with cystic fibrosis using a cutting-edge approach, allowing the lung cells to create normally functioning CFTR protein. This approach has the potential to provide a treatment for all people living with CF, regardless of mutation.
Laboratory studies to develop and test this potential therapy are underway.
This program is sponsored by Carbon Biosciences and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More